Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.

Lee, Kil-Yong; Park, Ji Won; Lee, Ki-Young; Cho, Sangsik; Kwon, Yoon-Hye; Kim, Min Jung; Ryoo, Seung-Bum; Jeong, Seung-Yong; Park, Kyu Joo
International journal of colorectal disease
2019Jan ; 87 ( 2 ) :.
저자 상세정보
Lee, Kil-Yong -
Park, Ji Won -
Lee, Ki-Young -
Cho, Sangsik -
Kwon, Yoon-Hye -
Kim, Min Jung -
Ryoo, Seung-Bum -
Jeong, Seung-Yong -
Park, Kyu Joo -
ABSTRACT
PURPOSE: After curative resection of stage II colon cancer, adjuvant chemotherapy with 5-fluorouracil/leucovorin (FL) or capecitabine is selectively recommended. However, there is little evidence of the effect of capecitabine on oncologic outcome in geriatric patients with stage II colon cancer compared to that of FL. The aim of this study was to determine the difference in recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) in patients older than 70?years of age with stage II colon cancer receiving capecitabine and FL.

METHODS: Patients over 70?years of age diagnosed with primary pathologic stage II colon cancer at the Seoul National University Hospital from January 2005 to December 2015 were included. A prospectively collected database was analyzed retrospectively. Patients were separated into an FL group and a capecitabine group. The primary outcomes were RFS, CSS, and OS.

RESULTS: Of the 154 included patients, 96 patients received FL and 58 patients received capecitabine. There was no difference between the two groups in RFS, CSS, or OS (p?=?0.763, p?=?0.221, and p?=?0.470, respectively) as measured by Kaplan-Meier analysis with log-rank test. Administration of capecitabine as compared to FL was not a factor affecting RFS (hazard ratio [HR] 0.503, 95% confidence interval [CI] 0.145-1.745), CSS (HR 1.519, 95% CI 0.348-6.629), or OS (HR 0.941, 95% CI 0.290-3.053) on multivariable analysis.

CONCLUSIONS: Capecitabine is a safe regimen in terms of oncologic outcomes compared with FL in older patients with stage II colon cancer.
keyword
5-Fluorouracil/leucovorin; Capecitabine; Colon cancer; Geriatric patients; Stage II
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
There was no difference between the two groups in RFS, CSS, or OS.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
KCD코드
ICD 03
건강보험코드